Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Osteoarthritis (OA) is a prevalent condition that affects individuals worldwide and is one of the leading causes of disability. Nevertheless, the underlying pathological mechanisms of OA remain inadequately understood. Current treatments for OA include non-drug therapies, pharmacological interventions, and surgical procedures. These treatments are mainly focused on alleviating clinical manifestations and improving patients' quality of life, but are not effective in limiting the progression of OA. The detailed understanding of the pathogenesis of OA is extremely significant for the development of OA treatment. Metabolic syndrome has become a great challenge for medicine and public health, In recent years, several studies have demonstrated that the metabolic syndrome and its individual components play a crucial role in OA. Consequently, this review summarizes the mechanisms and research progress on how metabolic syndrome and its components affect OA. The aim is to gain a deeper understanding of the pathogenesis of OA and explore effective treatment strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11688211 | PMC |
| http://dx.doi.org/10.3389/fendo.2024.1488481 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Characteristics and Management of Rare Metabolic Bone Diseases: An Audit of the Rare Metabolic Bone Disease Registry of India.
Calcif Tissue Int
September 2025
Department of Endocrinology, Post-Graduate Institute of Medical Education and Research (PGIMER), 001, Nehru Extension Block, Chandigarh, India.
Rare diseases, defined by the 2002 Rare Disease Act, affect fewer than 5 in 10,000 individuals. Rare metabolic bone diseases (MBDs), such as osteogenesis imperfecta, hypophosphatasia, osteopetrosis, and other unclassified disorders, can disrupt bone development and remodeling, posing diagnostic and management challenges. This study analyzed data from the rarembd.
View Article and Find Full Text PDFEstablished and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond.
Heart Lung Circ
September 2025
Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA,
Cardiovascular-kidney-metabolic (CKM) syndrome is a term that is increasingly used to describe interconnected conditions that lead to poor health outcomes, including cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. Historically, there have been very few targeted pharmacotherapies available that have changed cardiovascular outcomes for people with CKM syndromes; however, over the past decade, new pharmacologic options have rapidly expanded, with strong evidence for cardiovascular and kidney protective benefits in CKM conditions. Of note, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have emerged as key therapeutic options and are now widely guideline-endorsed.
View Article and Find Full Text PDFIs active commuting associated with metabolic syndrome in adults, adolescents, and children? a systematic review and meta-analysis.
Nutr Metab Cardiovasc Dis
July 2025
Instituto de Investigación e Innovación Biomédica de Cádiz, (INiBICA), Cádiz, Spain; GALENO Research Group, Department of Physical Education, Faculty of Education Sciences, University of Cádiz, Puerto Real, Cadiz, Spain; Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain; UGC
Aims: The prevalence of metabolic syndrome (MetS) is increasing annually across all age groups, raising the risk of morbidity, mortality, diabetes and cardiovascular disease in adults, adolescents, and children. Active commuting (AC) provides an opportunity to increase physical activity and reduce the MetS risk. The purpose of this study was to synthesize the available evidence on the prevalence of MetS and MetS risk factors in relation to AC vs non-active commuting among adults, adolescents, and children.
View Article and Find Full Text PDFThe influence of metabolic dysfunction on depressive symptom trajectories: A one-year follow-up study.
J Affect Disord
September 2025
Département de psychiatrie et d'addictologie, Université de Montréal, Montréal, Québec, Canada; Centre de recherche de l'Institut universitaire en santé mentale (CR-IUSMM), Université de Montréal, Montréal, Québec, Canada.
This study explored the role of metabolic syndrome (MetS) and health-related behaviors in the progression of depressive symptoms over a one-year naturalistic follow-up in patients with depressive disorder. Using data from 153 participants recruited through the Signature Biobank at a psychiatric emergency setting, we tested whether MetS mediated the relationship between health-related behaviors such as smoking, alcohol and drug use, and sleep, and depressive symptom trajectories. Linear mixed models revealed that while depressive symptoms significantly decreased over time, higher MetS score was associated with a slower improvement in depressive symptoms.
View Article and Find Full Text PDFPortal vein-enriched metabolites as intermediate regulators of the gut microbiome in insulin resistance.
Cell Metab
August 2025
Section of Integrative Physiology and Metabolism, Joslin Diabetes Center, Harvard Medical School, Boston, MA, USA. Electronic address:
Diet and obesity contribute to insulin resistance and type 2 diabetes, in part via the gut microbiome. To explore the role of gut-derived metabolites in this process, we assessed portal/peripheral blood metabolites in mice with different risks of obesity/diabetes, challenged with a high-fat diet (HFD) + antibiotics. In diabetes/obesity-prone C57BL/6J mice, 111 metabolites were portally enriched and 74 were peripherally enriched, many of which differed in metabolic-syndrome-resistant 129S1/129S6 mice.
View Article and Find Full Text PDF